Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17183393 | 1.00 | SIRT2 (0.61) | SIRT2SIRT1FOLH1SIRT3SYK | |
| SCHEMBL8113270 | 0.95 | SIRT2 (0.55) | SIRT2SIRT1FOLH1SYKPPARA | |
| SCHEMBL2072888 | 0.92 | SIRT2 (0.62) | SIRT2SIRT1SIRT3SYKMAPT | |
| SCHEMBL7821853 | 0.91 | FOLH1 (0.54) | SIRT2SIRT1FOLH1SYKPPARA | |
| SCHEMBL5971174 | 0.91 | PPARA (0.55) | SIRT2SIRT1FOLH1SYKPPARA | |
| SCHEMBL2776833 | 0.91 | PPARA (0.55) | SIRT2SIRT1FOLH1SYKPPARA | |
| SCHEMBL42877 | 0.91 | PPARA (0.55) | SIRT2SIRT1FOLH1SYKPPARA | |
| SCHEMBL14596694 | 0.89 | CTSL (0.51) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL31301793 | 0.89 | SYK (0.53) | SIRT2SIRT1SIRT3SYKPPARA | |
| SCHEMBL4837626 | 0.89 | SIRT2 (0.64) | SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914589-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S P A (IT) | 2017-08-30 | — | — | EP | disclosed |
| US-9365541-B2 | Compounds for use in the treatment of parasitic diseases | IRBM—SCIENCE PARK S.P.A. (IT) | 2016-06-14 | — | — | US | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-10-22 | — | — | US | disclosed |
| EP-1828171-B1 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2014-03-12 | — | — | EP | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-7863294-B2 | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-01-04 | — | — | US | disclosed |
| US-7799803-B2 | Hydroxamic acid compounds and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-7199134-B2 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | HDAC1, HDAC5, HDAC11 | SIRT2 44/4885SIRT1 21/4885FOLH1 2876/4885 |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | HDAC3, HDAC5, HDAC1 | SIRT2 25/4885SIRT1 23/4885FOLH1 521/4885 |
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | HDAC5, BRDT, HDAC1 | SIRT2 156/4885SIRT1 116/4885FOLH1 1369/4885 |
| US-20130172330-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | SIRT2 3624/4885SIRT1 2436/4885FOLH1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.